Cristina Gervasoni to Middle Aged
This is a "connection" page, showing publications Cristina Gervasoni has written about Middle Aged.
Connection Strength
0.170
-
Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021 05; 22(5):372-378.
Score: 0.015
-
Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020 11 19; 71(16):2276-2278.
Score: 0.015
-
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging. 2020 12; 37(12):925-933.
Score: 0.015
-
Different effects of glucocorticoids on darunavir plasma concentrations. Eur J Clin Pharmacol. 2019 May; 75(5):733-735.
Score: 0.013
-
Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. World J Biol Psychiatry. 2020 10; 21(8):651-657.
Score: 0.013
-
How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life? J Antimicrob Chemother. 2018 08 01; 73(8):2271-2273.
Score: 0.012
-
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
Score: 0.012
-
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. Antivir Ther. 2018; 23(5):467-469.
Score: 0.012
-
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
Score: 0.011
-
How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life? J Acquir Immune Defic Syndr. 2017 05 01; 75(1):e24-e26.
Score: 0.011
-
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017 Jun; 73(6):789-790.
Score: 0.011
-
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
Score: 0.011
-
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2021 03; 93(3):1421-1427.
Score: 0.004
-
Genomic Characterization of an ST1153 PVL-producing Methicillin Resistant Staphylococcus aureus Clinical Isolate in Italy. New Microbiol. 2019 Apr; 42(2):129-131.
Score: 0.003
-
Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Ther Drug Monit. 2019 02; 41(1):59-65.
Score: 0.003
-
Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):193-201.
Score: 0.003
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.003
-
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metab Pers Ther. 2017 05 24; 32(2):115-117.
Score: 0.003